Developmental Research Program

发展研究计划

• 批准号: 10470368
• 负责人: Jean-Pierre J. Issa
• 金额: $ 8.25万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10470368
• 关键词: American Association of Cancer Research; Award; Cancer Patient; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Development; Dreams; Ensure; Epigenetic Process; Fostering; Funding; Goals; Grant; Hematologic Neoplasms; Institutes; Institution; Laboratory Research; Leadership; Letters; Mainstreaming; Malignant Neoplasms; Mission; Modeling; Monitor; Nature; Peer Review; Pilot Projects; Process; Quality of life; Recording of previous events; Research; Research Peer Review; Research Personnel; Research Project Grants; Scientist; Seeds; Selection Criteria; Solid Neoplasm; Source; Structure; Therapeutic Studies; Time; Translating; Translational Research; University of Texas M D Anderson Cancer Center; cancer therapy; clinically relevant; epigenetic therapy; flexibility; high reward; high risk; improved; innovation; leukemia; novel; novel therapeutic intervention; pre-clinical; programs; research study; success; translational potential

PROJECT SUMMARY (Developmental Research Program) The specific objectives of the Developmental Research Program are to: 1. Publicize the availability of funds for pilot translational research studies in the field of Epigenetic Therapy for cancers. 2. Identify through this mechanism innovative projects with significant potential for developing and improving Epigenetic Therapies for cancers. 3. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE, specifically the Van Andel Institute-Stand Up To Cancer Epigenetics Dream Team (VAI-SU2C). 4. Enhance the communication between the SPORE leaders and VAI-SU2C Investigators to encourage the development of innovative epigenetics therapies for cancer. 5. Ensure program flexibility so that developmental projects that show promise can be: 1) funded for a second year; 2) encouraged to apply for peer-reviewed funding (i.e. R01); or 3) expanded to become full SPORE projects. The structure and processes of this program are modeled after a long-standing and successful Developmental Research Program within the MDACC Leukemia SPORE, and on the success of the VAI-SU2C Epigenetics Dream Team in soliciting, reviewing, awarding and monitoring developmental research project proposals. To achieve our aims, we will establish 1) specific criteria for selection and funding through a peer review mechanism, and 2) mechanisms for close monitoring of, and collaboration between the SPORE leaders and program awardees to enhance the quality of the translational research goals.

项目摘要（发展研究计划） 发展研究计划的具体目标是： 1。宣传在表观遗传疗法领域的试点翻译研究的资金可用性 对于癌症。 2。通过这种机制创新项目确定具有重要潜力和改进潜力的创新项目 癌症的表观遗传疗法。 3.鼓励与孢子内和孢子外科学家合作的合作， 特别是范·安德尔学院（Van Andel Institute）备受胜利的癌症表观遗传学梦想团队（VAI-SU2C）。 4。加强孢子领导者与VAI-SU2C调查人员之间的沟通，以鼓励 开发用于癌症的创新表观遗传学疗法。 5。确保计划灵活性，以便表现出承诺的发展项目可以：1）资助 第二年； 2）鼓励申请同行评审的资金（即R01）；或3）扩展到满 孢子项目。 该程序的结构和过程以长期而成功的发展为建模 MDACC白血病孢子中的研究计划，以及VAI-SU2C表观遗传学的成功 征求，审查，授予和监视发展研究项目建议的梦想团队。到 达到我们的目标，我们将建立1）通过同行评审机制选择和资金的特定标准， 2）孢子领导者与程序之间密切监控和协作的机制 获奖者以提高转化研究目标的质量。